Literature DB >> 23096413

Increased xCT expression correlates with tumor invasion and outcome in patients with glioblastomas.

Satoru Takeuchi1, Kojiro Wada, Terushige Toyooka, Nariyoshi Shinomiya, Hideyuki Shimazaki, Kuniaki Nakanishi, Kimihiro Nagatani, Naoki Otani, Hideo Osada, Yoichi Uozumi, Hirotaka Matsuo, Hiroshi Nawashiro.   

Abstract

BACKGROUND: xCT is a light chain of the cystine/glutamate antiporter system xc. Glutamate that is released by system xc plays an important role in the infiltration of glioblastoma (GBM) cells. Furthermore, increased glutathione synthesis by system xc may protect tumor cells against oxidative stress induced by radiotherapy and chemotherapy.
OBJECTIVE: To investigate whether the levels of xCT expression correlated with infiltrative imaging phenotypes on magnetic resonance imaging and outcomes in patients with GBMs.
METHODS: Forty patients with histologically confirmed primary GBMs were included in the study. Patient charts were retrospectively reviewed for age, sex, Karnofsky Performance Status Scale score, Mini-Mental State Examination score, magnetic resonance imaging features, xCT expression, isocitrate dehydrogenase 1 R132H expression, O-methylguanine-DNA methyltransferase promoter methylation status, type of surgery, progression-free survival, and overall survival.
RESULTS: In invasive margins, xCT expression was weak in 20 patients and strong in 20 patients. A Cox regression model revealed that a Karnofsky Performance Status Scale score less than 60 (hazard ratio [HR]: 4.525; P = .01), partial removal (HR: 2.839; P = .03), and strong xCT expression (HR: 4.134; P < .001) were significantly associated with shorter progression-free survival and that partial removal (HR: 2.865; P = .03), weak isocitrate dehydrogenase 1 R132H expression (HR: 15.729; P = .01), and strong xCT expression (HR: 2.863; P = .04) were significantly associated with shorter overall survival.
CONCLUSION: These findings suggest that xCT is an independent predictive factor in GBMs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23096413     DOI: 10.1227/NEU.0b013e318276b2de

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  42 in total

Review 1.  Non-invasive metabolic imaging of brain tumours in the era of precision medicine.

Authors:  Michelle M Kim; Abhijit Parolia; Mark P Dunphy; Sriram Venneti
Journal:  Nat Rev Clin Oncol       Date:  2016-07-19       Impact factor: 66.675

2.  Mutating Our Understanding of Brain Tumors and Seizures: Entrez IDH.

Authors:  Jong Woo Lee
Journal:  Epilepsy Curr       Date:  2017 Nov-Dec       Impact factor: 7.500

3.  Activation of the mTOR signaling pathway in peritumoral tissues can cause glioma-associated seizures.

Authors:  Yang Yuan; Wang Xiang; Liu Yanhui; Liang Ruofei; Luo Jiewen; Jiang Shu; Mao Qing
Journal:  Neurol Sci       Date:  2016-09-19       Impact factor: 3.307

4.  Cystine uptake through the cystine/glutamate antiporter xCT triggers glioblastoma cell death under glucose deprivation.

Authors:  Takeo Goji; Kazuhiko Takahara; Manabu Negishi; Hironori Katoh
Journal:  J Biol Chem       Date:  2017-10-16       Impact factor: 5.157

Review 5.  Glutamate transporters in the biology of malignant gliomas.

Authors:  Stephanie M Robert; Harald Sontheimer
Journal:  Cell Mol Life Sci       Date:  2013-11-27       Impact factor: 9.261

Review 6.  xCT: A Critical Molecule That Links Cancer Metabolism to Redox Signaling.

Authors:  Jinyun Liu; Xiaojun Xia; Peng Huang
Journal:  Mol Ther       Date:  2020-09-02       Impact factor: 11.454

7.  xCT expression modulates cisplatin resistance in Tca8113 tongue carcinoma cells.

Authors:  Peng Zhang; Wei Wang; Zhenhui Wei; L I Xu; Xuanning Yang; Yuanhong DU
Journal:  Oncol Lett       Date:  2016-05-16       Impact factor: 2.967

8.  Increased Expression of System xc- in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance.

Authors:  Monika D Polewski; Rosyli F Reveron-Thornton; Gregory A Cherryholmes; Georgi K Marinov; Kaniel Cassady; Karen S Aboody
Journal:  Mol Cancer Res       Date:  2016-09-22       Impact factor: 5.852

Review 9.  Main path and byways: non-vesicular glutamate release by system xc(-) as an important modifier of glutamatergic neurotransmission.

Authors:  Ann Massie; Séverine Boillée; Sandra Hewett; Lori Knackstedt; Jan Lewerenz
Journal:  J Neurochem       Date:  2015-09-29       Impact factor: 5.372

10.  Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition.

Authors:  Peng Ye; Junsei Mimura; Tomomi Okada; Hideyo Sato; Tao Liu; Atsushi Maruyama; Chikara Ohyama; Ken Itoh
Journal:  Mol Cell Biol       Date:  2014-07-07       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.